{
  "docId": "019de070-dce8-70ee-8639-85282f075771",
  "docSlug": "622e4280fc41e900213786c9a95190a7",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 40,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes footnotes explaining abbreviations and specific financial impacts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-dce8-70ee-8639-85282f075771/6",
  "deckHref": "/decks/019de070-dce8-70ee-8639-85282f075771",
  "deckJsonHref": "/decks/019de070-dce8-70ee-8639-85282f075771.json",
  "deckAnchorHref": "/decks/019de070-dce8-70ee-8639-85282f075771#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.93,
        "x": 0.035,
        "y": 0.23
      },
      "kind": "list",
      "text": "Total revenue +11%, incl. 4% from the pandemic COVID-19 vaccine. Total revenue excl. vaccine +7%\nGrowth: Oncology +16% and New CVRM +15%. Respiratory & Immunology -4%, impacted by stocking in Q1 2020. Emerging markets +10%\nCore operating profit +34%, supported by core OOI (+146%)\nCore EPS $1.63 (+53%), incl. 8% tax rate. Impact of pandemic vaccine $(0.03)\nPipeline progress underpins double-digit revenue growth\nESG: COVID-19 vaccine supplies increasing\nProposed Alexion acquisition passed several competition clearances; shareholder vote 11 May 2021\n2021 guidance reiterated: total revenue increase by a low teens percentage, accompanied by faster growth in core EPS to $4.75 to $5.00",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbde9f46-c750-427a-b5ce-7704924d46eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.93,
        "x": 0.035,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for first-quarter (Q1) 2021, unless stated otherwise. Guidance at CER and excludes the COVID-19 vaccine and Alexion. 1. Coronavirus disease; an infectious disease caused by a newly discovered coronavirus 2. New Cardiovascular, Renal and Metabolism comprising Farxiga, Brilinta, Diabetes and Renal 3. Other operating income 4. Earnings per share 5. Environmental, social and (corporate) governance (topics).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d20548ed-eb17-4bdc-bf18-9da918b59da1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.48,
        "x": 0.035,
        "y": 0.04
      },
      "kind": "title",
      "text": "Q1 2021: solid start to the year",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6efdacd5-96fa-4d17-9f61-4629086cccf1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "349a6625-c44e-49db-8dff-855a7448a045",
      "evidence": "Q1 2021: solid start to the year, list of bullet points",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "054d98ff-d2ed-4695-ab1b-11ddceec292c",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The slides highlight the progress in the late-stage pipeline and vaccine contribution",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}